News
9d
Clinical Trials Arena on MSNFirst subject dosed in Vantage’s Phase II trial for diabetic retinopathyVantage Biosciences has dosed the first subject in the randomised Phase II trial of oral therapy VX-01 to treat NPDR.
The incidence rate of one of the most severe forms of the disease, proliferative diabetic retinopathy, fell by almost 300% ...
Diabetic retinopathy involves the changes for the blood vessels in your eye due to the high sugars that are in your body from diabetes, if you're a diabetic and you notice changes to your vision ...
The following is a summary of “Recent advances and applications of optical coherence tomography angiography in diabetic ...
Diabetic retinopathy develops when you have high blood ... Vitrectomy is a surgical procedure for severe or treatment-resistant DME. It involves removing the vitreous humor to treat structural ...
DR was graded according to early Treatment Diabetic Retinopathy (ETDRS ... 22 patients (11.1%) with severe NPDR and 25 patients (25.1%) with proliferative DR (PDR). There were significant relation ...
Below a specific threshold, FCP exerts a protective effect, but above that threshold the protective effect becomes uncertain.
Diabetic retinopathy (DR), a serious eye condition caused by damage to the blood vessels in the retina—the light-sensitive tissue at the back of the eye—is a major public health concern in India.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results